Skip to content

Induced Pluripotent Stem Cells (iPSCs): Science & Approvals

Curated by Michel Oliver, Restore Wellness Group · Independent Health Researcher & Patient Advocate · Last reviewed October 2026 · How we research

About this guide: We are independent patient researchers, not medical doctors. We review peer-reviewed literature (PubMed), government trial registries and regulators’ guidance, plus documented patient reports, to help you navigate clinic options and spot predatory marketing. How we research.

IN SHORT

Induced pluripotent stem cells (iPSCs) are adult cells, such as skin or blood cells, reprogrammed in the lab into an embryo-like state that can become almost any cell type. In March 2026 Japan gave the first conditional, time-limited approvals for iPSC-derived therapies, for Parkinson’s disease and heart failure; none is approved in the US or EU.

What is induced pluripotent stem cells (ipscs)?

iPSCs were first made from mouse cells in 2006 and human cells in 2007 by Shinya Yamanaka’s team in Kyoto. The discovery won the 2012 Nobel Prize in Physiology or Medicine, shared with John Gurdon. Because they can become nearly any cell, iPSCs offer a way to make replacement cells without using embryos. They are also widely used to study disease and test drugs.

How it works

Adult cells are given a small set of genetic ‘switches’ that reset them to a pluripotent state. The iPSCs are then guided, over weeks or months, to become a specific cell type, such as dopamine nerve cells or heart muscle. These cells are tested for purity and safety, then transplanted, for example by surgery into the brain or as sheets on the heart. Cells may come from the patient or from a matched donor bank.

Legal status

In the US, iPSC-derived therapies are regulated as biologics (Section 351) and are only available in FDA-authorised clinical trials. In the EU, they are advanced therapy medicinal products, and none is authorised. Japan, which ran the first iPSC transplant in 2014, granted conditional, time-limited approval in March 2026 to an iPSC-derived dopamine cell therapy for Parkinson’s and an iPSC-derived heart muscle cell product for heart failure. Any clinic selling ‘iPSC treatment’ outside a trial should be treated with great caution.

What the evidence shows

The first human iPSC transplant, in 2014 in Japan, placed retinal cells in a patient with macular degeneration, mainly to test safety. A 2025 Kyoto trial in Nature transplanted iPSC-derived dopamine cells into seven people with Parkinson’s; there were no serious adverse events or tumours, and four of six evaluated showed motor improvement off medication.

That small trial supported Japan’s conditional approval, which requires further data. Dozens of other pluripotent cell trials are under way for eye disease, spinal cord injury, diabetes and heart disease. Evidence is still early, small-scale and not yet proof of lasting benefit.

Commonly marketed for

  • Parkinson’s disease
  • Heart failure
  • Age-related macular degeneration
  • Spinal cord injury
  • Type 1 diabetes
  • Anti-ageing (unproven marketing)

Cost

There is no legitimate consumer price for iPSC therapy. Outside Japan’s two conditionally approved products, iPSC treatments are only available in clinical trials, which usually do not charge participants; offers to sell iPSC treatment directly are a red flag.

Risks

  • Tumour formation if immature cells remain
  • Immune rejection when donor cells are used, often requiring immune-suppressing drugs
  • Surgical risks of transplantation, such as brain surgery
  • Genetic changes that can arise during reprogramming and growth
  • Exploitation by clinics falsely selling ‘iPSC’ products

Questions to ask first

  1. Is this an approved product or a registered, regulator-authorised clinical trial?
  2. What type of cell is being made from iPSCs, and how is it checked for leftover immature cells?
  3. Will I need immune-suppressing drugs, and for how long?
  4. What follow-up is planned to monitor long-term safety, including tumours?
Before You Pay: The Stem Cell Clinic Checklist – free 9-page PDF
Free patient guide

Before You Pay: The Stem Cell Clinic Checklist

  • 20 questions every legitimate clinic should answer in writing
  • A red-flag scorecard to spot unregulated marketing
  • Realistic 2026 cost ranges: US, Mexico, Panama & Europe
  • How to find a registered clinical trial

We’ll email you a link to confirm. No spam, unsubscribe any time. See our Privacy Policy.

Induced Pluripotent Stem Cells (iPSCs): FAQs

Who discovered iPSCs?

Shinya Yamanaka’s team at Kyoto University reported them in 2006 (mouse) and 2007 (human). He shared the 2012 Nobel Prize with John Gurdon.

Are iPSC treatments approved anywhere?

Yes, but only in Japan, which granted conditional, time-limited approval in March 2026 for products treating Parkinson’s disease and heart failure. None is approved in the US or EU.

Did the Parkinson’s trial cure patients?

No. In a seven-person trial, most showed some motor improvement and no tumours. Patients still need their usual medication.

Are iPSCs the same as embryonic stem cells?

They behave similarly, but iPSCs are made from adult cells, so no embryos are used.

Can I buy iPSC treatment at a clinic?

Legitimate iPSC therapies are not sold directly to consumers. Clinics offering ‘iPSC’ infusions outside trials should be avoided.

Related guides

Sources

Last reviewed October 2026. For general information only — not medical advice. We do not endorse any clinic or product. Always consult a qualified, licensed healthcare professional. See our medical disclaimer and editorial policy.